Titan Biotech Ltd Stock Hits All-Time High of Rs.400 on 13 Mar 2026

Stock Performance and Market Context

On the day of this record, Titan Biotech’s stock touched an intraday high of Rs.400, representing a 3.17% increase, before closing with a modest gain of 0.59%. This outperformed the Sensex, which declined by 0.70% on the same day. The stock’s recent trend shows a slight reversal after seven consecutive days of gains, yet it remains firmly above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bullish momentum.

Over various time horizons, Titan Biotech has demonstrated exceptional returns relative to the broader market. The stock surged by 41.18% over the past week and 60.87% in the last month, while the Sensex declined by 4.33% and 8.62% respectively. The three-month performance stands at an impressive 79.24%, compared to the Sensex’s 11.45% fall. Over the last year, Titan Biotech’s return of 352.44% dwarfs the Sensex’s modest 2.27% gain. Year-to-date, the stock has risen 85.04%, while the Sensex has dropped 11.40%. The long-term trajectory is even more striking, with a 3-year return of 816.14% and a 5-year return of 892.87%, far exceeding the Sensex’s 29.64% and 48.65% gains respectively. Over a decade, the stock has multiplied by over 50 times, delivering a staggering 5038.34% return against the Sensex’s 205.45%.

Financial Highlights Underpinning the Rally

Titan Biotech’s recent quarterly results have been notably strong, contributing to the stock’s upward trajectory. The company reported its highest-ever quarterly figures with Profit Before Tax Less Other Income (PBT LESS OI) at Rs.9.30 crores, Net Sales at Rs.56.51 crores, and Profit Before Depreciation, Interest and Tax (PBDIT) at Rs.10.84 crores. The operating profit margin for the quarter reached a peak of 19.18%, while the quarterly Profit After Tax (PAT) stood at Rs.8.53 crores, with Earnings Per Share (EPS) at Rs.10.33.

These results represent a net profit growth of 107.11% and mark the second consecutive quarter of positive earnings, reinforcing the company’s improving profitability. The company’s low average debt-to-equity ratio of 0.04 times further supports its financial stability, reflecting a conservative capital structure with negligible leverage.

Valuation metrics as of 13 Mar 2026 show a Price-to-Earnings (P/E) ratio of 59x and a Price-to-Book Value (P/BV) of 9.63x, indicating a premium valuation relative to historical levels and peers. The Enterprise Value to EBITDA ratio stands at 48.02x, while the PEG ratio is 2.81x, reflecting the relationship between price, earnings growth, and valuation. Dividend yield remains modest at 0.10%, with a payout ratio of 6.65% and the latest dividend declared at Rs.2 per share.

Technical and Quality Assessments

The technical outlook for Titan Biotech remains bullish, with multiple indicators confirming the positive trend. Weekly and monthly MACD, Bollinger Bands, KST, and Dow Theory signals all align in favour of continued strength. The stock’s immediate support is anchored at Rs.74.73, its 52-week low, while the 52-week high of Rs.400 now serves as a key resistance level.

Quality assessments classify Titan Biotech as an average quality company based on long-term financial performance. The company boasts a strong return on capital employed (ROCE) averaging 25.43% and a return on equity (ROE) of 21.23%, both indicative of efficient capital utilisation and profitability. The management risk is rated average, with below-average growth in operating profit over the past five years at an annualised rate of -6.32%. However, sales growth over the same period has been a steady 8.72% CAGR. The company maintains a strong interest coverage ratio of 26.27x and zero promoter share pledging, underscoring financial prudence.

Long-Term Performance and Market Position

Titan Biotech’s market capitalisation categorises it as a micro-cap stock, yet its performance has consistently outpaced broader indices and sector benchmarks. The stock’s 5-year return of 892.87% and 10-year return exceeding 5000% highlight its remarkable growth trajectory. Despite this, institutional ownership remains minimal, with domestic mutual funds holding a negligible 0.03% stake, suggesting limited institutional participation at current valuations.

The company’s valuation is considered very expensive, with a high Price-to-Book ratio and premium multiples compared to peers. The PEG ratio of 2.8 indicates that the stock’s price growth has outpaced earnings growth, a factor that investors may weigh in their analysis.

Summary of Key Metrics and Market Standing

Titan Biotech’s journey to its all-time high is supported by a combination of strong quarterly earnings, consistent sales growth, and a robust balance sheet with minimal debt. The stock’s technical indicators and moving averages confirm a bullish trend, while its long-term returns significantly outperform the Sensex and sector averages.

However, the company’s valuation metrics reflect a premium pricing environment, with elevated P/E and P/B ratios and a PEG ratio above 2.5. The relatively low institutional holding and modest dividend yield also characterise its current market profile. These factors contribute to a nuanced picture of Titan Biotech’s market position as it celebrates this historic price milestone.

Overall, Titan Biotech Ltd’s attainment of Rs.400 per share marks a noteworthy achievement in its corporate history, reflecting sustained financial strength and market confidence within the Specialty Chemicals sector.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today